RECOVER: Designing a Large Language Model-based Remote Patient Monitoring System for Postoperative Gastrointestinal Cancer Care

Cancer surgery is a key treatment for gastrointestinal (GI) cancers, a group of cancers that account for more than 35% of cancer-related deaths worldwide, but postoperative complications are unpredictable and can be life-threatening. In this paper, we investigate how recent advancements in large language models (LLMs) can benefit remote patient monitoring (RPM) systems through clinical integration by designing RECOVER, an LLM-powered RPM system for postoperative GI cancer care. To closely engage stakeholders in the design process, we first conducted seven participatory design sessions with five clinical staff and interviewed five cancer patients to derive six major design strategies for integrating clinical guidelines and information needs into LLM-based RPM systems. We then designed and implemented RECOVER, which features an LLM-powered conversational agent for cancer patients and an interactive dashboard for clinical staff to enable efficient postoperative RPM. Finally, we used RECOVER as a pilot system to assess the implementation of our design strategies with four clinical staff and five patients, providing design implications by identifying crucial design elements, offering insights on responsible AI, and outlining opportunities for future LLM-powered RPM systems.

Patient ADE Risk Prediction through Hierarchical Time-Aware Neural Network Using Claim Codes

Adverse drug events (ADEs) are a serious health problem that can be life-threatening. While a lot of studies have been performed on detect correlation between a drug and an AE, limited studies have been conducted on personalized ADE risk prediction. Among treatment alternatives, avoiding the drug that has high likelihood of causing severe AE can help physicians to provide safer treatment to patients. Existing work on personalized ADE risk prediction uses the information obtained in the current medical visit. However, on the other hand, medical history reveals each patient's unique characteristics and comprehensive medical information. The goal of this study is to assess personalized ADE risks that a target drug may induce on a target patient, based on patient medical history recorded in claims codes, which provide information about diagnosis, drugs taken, related medical supplies besides billing information. We developed a HTNNR model (Hierarchical Time-aware Neural Network for ADE Risk) that capture characteristics of claim codes and their relationship. The empirical evaluation show that the proposed HTNNR model substantially outperforms the comparison methods, especially for rare drugs.